Pharmacokinetics-Based Pediatric Dose Evaluation and Optimization Using Saliva - A Case Study.

Anliker-Ort, Marion; Rodieux, Frédérique; Ziesenitz, Victoria C; Atkinson, Andrew; Bielicki, Julia A; Erb, Thomas O; Gürtler, Nicolas; Holland-Cunz, Stefan; Duthaler, Urs; Rudin, Deborah; Haschke, Manuel; van den Anker, John; Pfister, Marc; Gotta, Verena (2024). Pharmacokinetics-Based Pediatric Dose Evaluation and Optimization Using Saliva - A Case Study. Journal of clinical pharmacology, 64(7), pp. 810-819. Wiley 10.1002/jcph.2428

[img]
Preview
Text
The_Journal_of_Clinical_Pharma_-_2024_-_Anliker_Ort_-_Pharmacokinetics_Based_Pediatric_Dose_Evaluation_and_Optimization.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial (CC-BY-NC).

Download (907kB) | Preview

Understanding pharmacokinetics (PK) in children is a prerequisite to determine optimal pediatric dosing. As plasma sampling in children is challenging, alternative PK sampling strategies are needed. In this case study we evaluated the suitability of saliva as alternative PK matrix to simplify studies in infants, investigating metamizole, an analgesic used off-label in infants. Six plasma and 6 saliva PK sample collections were scheduled after a single intravenous dose of 10 mg/kg metamizole. Plasma/saliva pharmacometric (PMX) modeling of the active metabolites 4-methylaminoantipyrine (4-MAA) and 4-aminoantipyrine (4-AA) was performed. Various reduced plasma sampling scenarios were evaluated by PMX simulations. Saliva and plasma samples from 25 children were included (age range, 5-70 months; weight range, 8.7-24.8 kg). Distribution of metamizole metabolites between plasma and saliva was without delay. Estimated mean (individual range) saliva/plasma fractions of 4-MAA and 4-AA were 0.32 (0.05-0.57) and 0.57 (0.25-0.70), respectively. Residual variability of 4-MAA (4-AA) in saliva was 47% (28%) versus 17% (11%) in plasma. A simplified sampling scenario with up to 6 saliva samples combined with 1 plasma sample was associated with similar PK parameter estimates as the full plasma sampling scenario. This case study with metamizole shows increased PK variability in saliva compared to plasma, compromising its suitability as single matrix for PK studies in infants. Nonetheless, rich saliva sampling can reduce the number of plasma samples required for PK characterization, thereby facilitating the conduct of PK studies to optimize dosing in pediatric patients.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of General Internal Medicine (DAIM) > Clinic of General Internal Medicine

UniBE Contributor:

Haschke, Manuel Martin

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1552-4604

Publisher:

Wiley

Language:

English

Submitter:

Pubmed Import

Date Deposited:

27 Mar 2024 16:19

Last Modified:

28 Jun 2024 00:13

Publisher DOI:

10.1002/jcph.2428

PubMed ID:

38497339

Uncontrolled Keywords:

children infants metamizole pharmacokinetics pharmacometrics saliva

BORIS DOI:

10.48350/194472

URI:

https://boris.unibe.ch/id/eprint/194472

Actions (login required)

Edit item Edit item
Provide Feedback